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INTRODUCTION: Time from diagnosis to treatment initiation for many
cancers is lengthening. During the COVID pandemic, many institutions were
forced to postpone cancer treatment to reallocate resources, despite the unclear
impact of treatment delays. This study sought to investigate the association
between time to treatment initiation (TTI) and overall survival in patients
with hepatopancreatobiliary (HPB) cancers. METHODS: The National Cancer
Database (NCDB) was queried for patients diagnosed with de novo cancers of
the pancreas, liver, and intrahepatic and extrahepatic bile ducts between 2004
and 2017. Kaplan-Meier survival analysis and Cox regression were used to
investigate the association between TTI and overall survival for each cancer type,
stratiﬁed by stage. Multivariable linear regression identiﬁed factors associated
with longer TTI. RESULTS: Of 318,931 patients with HPB cancer, median TTI
across all cancers was 31 days, ranging from 26 days for pancreas cancer to 48
days for liver cancer. Longer TTI was associated with increased mortality in
patients with stages I, II, and III extrahepatic bile duct (EHBD) cancer (Figure
1), and stage I pancreatic adenocarcinoma. Compared to TTI of 3 to 30 days,
the risk-adjusted hazard ratios for stage I EHBD cancer for TTI 31 to 60, 61
to 90, and *90 days were 1.17 [95% CI 1.07–1.29], 1.39 [1.21–1.59], and 1.63
[1.40–1.90], respectively. For the same time frames, hazard ratios in stage I
pancreatic cancer were 1.08 [1.03–1.13], 1.19 [1.11–1.28], and 0.99 [0.90–1.09],
respectively. Factors most strongly associated with increased TTI for all cancers
included treatment with radiation only (` = +14.1 days, p< 0.001), early stage
disease (+13.8 days for stage I vs. stage IV, p< 0.001), Black race (+4.4 days,
p< 0.001), Hispanic ethnicity (+4.2 days, p< 0.001), and treatment in the West
(+3.9 days vs. Northeast, p< 0.001). CONCLUSIONS: Delayed initiation
of deﬁnitive therapy leads to increased mortality in stage I-III EHBD and
stage I pancreatic cancer. Some patients, including Blacks and Hispanics, are
more likely to experience delayed care. Treatment initiation for these cancers
should be expedited, and pandemic-related postponements should be avoided
if possible.

INTRODUCTION: Previous studies have shown signiﬁcant disparities
in pancreas cancer outcomes in African American (AA) compared to non-AA
patients. Pancreas surgery continues to be associated with signiﬁcant morbidity,
however, there is little reported data on pancreas surgical outcomes by race.
We sought to evaluate how race would affect surgical outcomes in an urban
tertiary care center for patients undergoing pancreas surgery. METHODS:
A retrospective single-center analysis of patients undergoing pancreas
surgery between January 2013 and September 2021 was performed. Patient
demographics and post-surgical complications were collected and stratiﬁed by
race. Area Deprivation Index (ADI) was used to determine patient socioeconomic
status. Charlson Comorbidity Index (CCI) was calculated for comorbidities.
Clavien-Dindo (CD) complications, as well as postoperative pancreatic ﬁstula
(POPF), delayed gastric emptying (DGE) and postpancreatectomy hemorrhage
(PPH) were evaluated. Patient reoperation, readmission, and mortality in the
30- and 90- day period were collected and univariate and multivariate analyses
were performed.RESULTS: Among 461 patients, 82% (N = 378) were nonAA and 18% (N = 83) were AA. Age and sex were found to be signiﬁcantly
different between the two groups, while ADI and CCI were not. Length of stay
(LOS), POPF, PPH, PPH grade C and intra-abdominal abscess (IAA) were
found to be signiﬁcant on univariate analysis in the AA cohort. On multivariate
analysis, LOS (OR 4.0; 95% CI 2.0-5.7; p < 0.001), POPF (OR 0.6; 95% CI
0.4-1.0; p = 0.043), PPH (OR 0.5; 95% CI 0.2-0.9; p = 0.022), PPH grade C
(OR 0.2; 95% CI 0.1-0.7; p = 0.017) and IAA (OR 0.4; 95% CI 0.2-0.9; p =
0.017) were still signiﬁcantly higher in the AA cohort. CONCLUSIONS: AA
patients undergoing pancreas surgery were noted to have a longer LOS, higher
incidence of POPF, PPH and IAA compared to non-AA patients. However, no
signiﬁcant difference was seen in reoperation rates, major CD complications, or
30- and 90-day readmission. Elucidating patient selection, tumor biology, and
preoperative treatment algorithms may shed additional insight on the differences
in surgical outcomes in this particular patient cohort.
Table. Patient demographics, pathologies, surgery types and outcomes

Figure 1. Kaplan-Meier survival analysis for patients with stage I (A), II
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